Invivotek的动态

Check out the highlights from the SRA 2024 meeting! Our panel discussed funding opportunities for young scholars and marginalized identities in the session titled, ""Funding Perspectives from NIH, NSF, and IES."" Discover more resources for students and early-career scholars here: https://bit.ly/3WAHoJ5

The inaugural cohort of CIFAR’s Next Generation Pilot initiative includes Sarah Power, PhD, who had the opportunity to jointly work with CIFAR Azrieli Global Scholar Tomás Ryan (Trinity College Dublin), Fellow Paul Frankland (The Hospital for Sick Children, Toronto) and Advisor Ulman Lindenberger (Max Planck Institute for Human Development) on cross-species work related to infantile amnesia and early “forgetting.” Find out how we’re supporting the next generation of research leaders in our 2023-24 Impact Report: https://lnkd.in/gXV9i26P?

?? Major NIH peer review changes effective Jan 25, 2025! Updates include a simplified review framework, revised criteria for fellowships/training grants, & updated forms. Learn more & access resources to navigate the changes: https://lnkd.in/eEh46D4q

Twenty projects from Te Herenga Waka—Victoria University of Wellington have been awarded grants in the latest round of Te Pūtea Rangahau a Marsden, the Marsden Fund.? ? Standard grants, which provide up to $960,000 over three years, were awarded to 11 projects as diverse as research into the mathematical foundation of quantum mechanics, enhancing the measurement of reputation, and how 18th century poety influenced settlers' treaty making with Indigenous peoples.? ? Fast-start grants, worth $360,000 each, were awarded to 9 projects, covering topics such as investigating digital experiences for people with ADHD, protection of infants from infectious disease, and the rise of indigenous non-religion.? https://lnkd.in/g4pTMkgX

Finding the right funding for your research can be challenging, but there are resources available that can help. Explore our interactive decision tree to help identify a potential fit to one or more of the four major research project grant types that NIGMS supports. This tool is designed for independent investigators who are new to the NIH grant process and are conducting research within our mission. Learn more in the #NIGMSFeedbackLoop blog: go.nih.gov/F5j9VXO. #FundingOpportunities

?? Biotech isn’t built in isolation. We all love stories of lone genius founders making breakthroughs in their basements. But the reality? Thriving companies are products of thriving ecosystems. Why? Because the right location can mean the difference between a lonely uphill climb and an unstoppable momentum of resources, talent, and partnerships. Consider this: ?? Companies in biotech hubs (Boston, San Francisco, etc.) are 4x more likely to secure funding than those outside established life sciences clusters. ?? The branding and visibility that come with being in a strong ecosystem can shave years off your path to traction. Yet too many founders try to go it alone—fighting for resources without local investors, support networks, or access to top-tier talent. But biotech success is never a solo act. It takes a connected network of stakeholders—real estate developers, policymakers, research institutions, and investors—to build an environment where startups thrive. We believe #Atlanta has that growth potential. After all, Radyus Research was built in Atlanta. That’s why we're excited our CEO Marta New, PhD, MBA will join the Urban Land Institute Women's Leadership Initiative conversation this Wednesday with real estate innovators, city and state leaders, and other life sciences champions to discuss how cross-vertical collaboration can boost Atlanta's and Georgia’s biotech future. Biotech CEOs: Where you plant your company matters! Location is more than geography—it’s fuel for growth, innovation, and resilience. If we want to build the future of medicine, we need ecosystems that build us up. Let’s make that future happen, together. Starting right here at home! #BiotechEcosystem #AtlantaBiotech #LifeSciences #CrossSectorCollaboration

Gregory H. Symmes has been named the chief operating officer of the National Academy of Sciences (NAS) and executive officer of the National Research Council (NRC), the operating arm of the NAS. In partnership with the National Academy of Engineering and National Academy of Medicine, the NAS and NRC informs public discourse and policymaking with evidence-based advice. Read more: https://ow.ly/VEkV50ULnh6

Reminder, if you are based in regional, rural and remote Australia and undergoing postgraduate studies, you'll want to catch this webinar with the brilliant Daniel Wadsworth!

Any real reform of NIH will make a lot of scientists cry-- the mediocre ones who thrive in the current system. Already many have taken a "sky is falling" view of even minor pauses. They pretend like study sections meet and then pass out money the next week. They pretend that NIH is not a cauldron of nepotism and favoritism preferentially funding mediocre work (this is well documented). They act like grant giving has been well studied, when it has never been subjected to randomized appraisal against alternative methods that are less onerous-- such as modified lottery. Unfortunately it will be difficult to judge the success or failure of reform from scientists' opinions, who will cry either way. I plan on looking at the details and writing about it on my substack.

Understanding the biology of Parkinson’s disease and turning that knowledge into better treatments is a complex undertaking. In the newest episode of our award-winning Parkinson’s Science POV series, scientists at MJFF discuss how they are tackling this problem from every angle. In the episode, we sit down with MJFF Chief Program Officer Sohini Chowdhury and other staff members to discuss their work, the projects they’re most proud of and their hopes for 2025. Whether it’s using cutting-edge imaging to get a picture of the disease in the brain or working with the community to develop better options to treat walking difficulties, our researchers are collaborating to discover the next wave of treatment options and close in on a cure. Listen to the episode: https://bit.ly/4g3nPSp